Merus (MRUS) Earns Media Sentiment Score of 0.05
Media headlines about Merus (NASDAQ:MRUS) have been trending somewhat positive recently, according to Accern. The research group identifies positive and negative media coverage by reviewing more than 20 million news and blog sources in real time. Accern ranks coverage of public companies on a scale of negative one to one, with scores closest to one being the most favorable. Merus earned a news impact score of 0.05 on Accern’s scale. Accern also assigned media coverage about the biotechnology company an impact score of 43.6568126847622 out of 100, meaning that recent media coverage is somewhat unlikely to have an effect on the stock’s share price in the immediate future.
Here are some of the news headlines that may have impacted Accern Sentiment Analysis’s analysis:
- Merus (MRUS) Lifted to “Hold” at BidaskClub (americanbankingnews.com)
- Merus (MRUS) Receives Consensus Rating of “Hold” from Analysts (americanbankingnews.com)
- Merus N.V. to Host Earnings Call (finance.yahoo.com)
- Merus Announces Recent Corporate Developments and Financial Results for the Fourth Quarter and Full Year 2017 (finance.yahoo.com)
NASDAQ:MRUS opened at $18.10 on Friday. The firm has a market cap of $350.60, a price-to-earnings ratio of -4.22 and a beta of 0.08. Merus has a 1 year low of $13.23 and a 1 year high of $23.75.
Merus Company Profile
Merus N.V., a clinical-stage immuno-oncology company, engages in developing bispecific antibody therapeutics. Its lead bispecific antibody candidate is MCLA-128, which is in Phase I/II clinical trials in Europe for the treatment of various solid tumors, including breast, gastric, and ovarian cancers.
Receive News & Ratings for Merus Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Merus and related companies with MarketBeat.com's FREE daily email newsletter.